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Abstract
Background: Legionella is a common cause of bacterial pneumonia. Community-acquired [CAL] and hospital-
acquired legionellosis [HAL] may have different presentations and outcome. We aimed to compare clinical 
characteristics and examine predictors of mortality for CAL and HAL.
Methods: We identified hospitalized cases of legionellosis in 4 Danish counties from January 1995 to December 2005 
using the Danish national surveillance system and databases at departments of clinical microbiology. Clinical and 
laboratory data were retrieved from medical records; vital status was obtained from the Danish Civil Registration 
System. We calculated 30- and 90-day case fatality rates and identified independent predictors of mortality using 
logistic regression analyses.
Results: We included 272 cases of CAL and 60 cases of HAL. Signs and symptoms of HAL were less pronounced than 
for CAL and time from in-hospital symptoms to legionellosis diagnosis was shorter for CAL than for HAL (5.5 days vs. 12 
days p < 0.001). Thirty-day case fatality was 12.9% for CAL and 33.3% for HAL; similarly 90-day case fatalities in the two 
groups were 15.8% and 55.0%, respectively. In a logistic regression analysis (excluding symptoms and laboratory tests) 
age >65 years (OR = 2.6, 95% CI: 1.1-5.9) and Charlson comorbidty index ≥2 (OR = 2.7, 95% CI: 1.1-6.5) were associated 
with an increased risk of death in CAL. We identified no statistically significant predictors of 30-day mortality in HAL.
Conclusions: Signs and symptoms were less pronounced in HAL compared to CAL. Conversely, 30-day case fatality 
was almost 3 times higher. Clinical awareness is important for the timely diagnosis and treatment especially of HAL. 
There is a need for further studies of prognostic factors in order to improve the therapeutic approach to legionellosis 
and potentially reduce mortality.
Background
Legionellosis is caused by exposure to the small intracel-
lular gram-negative bacterium Legionella from water
sources in the indoor or outdoor environment [1]. Two to
fifteen percent of all hospitalizations for community-
acquired pneumonias in Europe and North America are
caused by Legionella and recent studies suggest that rates
of legionellosis may be increasing [2]. The optimal antibi-
otic treatment of legionellosis has never been investigated
in a randomized clinical trial, but most clinicians use
either macrolides or fluoroquinolones [3,4] alone or com-
bined with rifampicin [5].
The most common presentation of legionellosis is
pneumonia which is often severe but almost any manifes-
tation of the disease has been seen ranging from a mild
self-limiting flu-like illness called Pontiac fever to any
extrapulmonary affection to multi organ failure and
death. Although no single finding in legionellosis is
pathognomonic several findings are characteristic [6]
such as relative bradycardia, hyponatriemia, elevation in
serum creatinine kinase, diarrhea, confusion and
impaired liver- and kidney-function [6-8].
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Prognostic factors in legionellosis are not well
described but delay in appropriate antibiotic therapy has
been associated with increased mortality [9]. Other
potential prognostic factors include: Delayed hospitaliza-
tion, long duration of symptoms prior to ICU admission,
high SAPS II or APACHE II score, and hyponatriemia [9-
11]. Most previous studies were small and did not analyze
prognostic factors according to whether legionellosis was
community- or hospital-acquired [9-11].
We designed a 10-year population-based historical
cohort study in four Danish counties with the following
aims: 1) To evaluate differences between community-
acquired and hospital-acquired cases of legionellosis
[CAL and HAL]; 2) To compare 30- and 90-day case fatal-
ity for patients with CAL and HAL; 3) To assess predic-
tors of 30-day mortality for these 2 forms of legionellosis.
A better understanding of clinical presentation and prog-
nostic factors for legionellosis may optimize our thera-
pe u t i c  a p p r o a c h  a n d  m a n a g e m e n t  o f  l e gi o n e l l o s i s,  a n d
thus reduce mortality and morbidity.
Methods
Study setting and population
We included patients ≥15 years of age hospitalized with
legionellosis in Aarhus, Viborg, Ringkøbing, and North
Jutland counties (total population approximately 1.6 mil-
lion)[12] between January 1995 and December 2005. All
county residents have access to universal tax-supported
health care provided by general practitioners and public
hospitals.
Since 1968, all residents in Denmark have been regis-
tered in the Civil Registration System and given a unique
identification number, which is used in all national regis-
tries to identify that person. The Civil Registration Sys-
tem provides daily updated information on death and
emigration.
Diagnosis of legionella infection
Diagnostic tests for legionellosis, a notifiable disease in
Denmark, were performed at Statens Serum Institut
(SSI), Copenhagen and the regional departments of clini-
cal microbiology. Within the surveillance system cases
are classified as either definitive, presumptive or unlikely
cases. According to Danish guidelines a definitive case is
a patient with at least one of the following: 1) Culture iso-
lation of Legionella species; 2) Detection of Legionella
antigen in urine with a level of antigen >10 aU/ml; 3)
Fourfold rise or fall of immunofluorescence titres against
L. pneumophila serogroup 1, 3 or 6 obtained with paired
serum specimen, provided a titer of at least 1:128 was
obtained; 4) Detection of L. pneumophila DNA by PCR
in a sample from the lower airways or a Legionella anti-
body titer >1:256 against L. pneumophila serogroup 1, 3
or 6 combined with Legionella urinary antigen test >5
aU/ml and <10 aU/ml, or 5) Positive Legionella PCR and
Legionella antibody titer >1:256 against L. pneumophila
serogroup 1, 3 or 6. A presumptive case is defined as a
patient with at least one of the following: 1) Legionella
urinary antigen test >5 aU/ml and < 10 aU/ml; 2) Positive
Legionella PCR; 3) An antibody titer >1:256 against L.
pneumophila serogroup 1, 3 or 6; 4) A fourfold rise or fall
of antibody titers with paired sera against L. pneumophila
serogroup 2, 4 or 5 or against L. micdadei or L. bozemanii
provided that a titer of at least 1:128 is reached; 5) A com-
patible history of legionellosis during an outbreak but
without diagnostic tests being obtained, or 6) Any combi-
nation of diagnostic results that justifies a classification as
a possible case. Only definitive and presumptive cases
were included in the study as described previously [13].
To ensure that no cases of legionellosis were overlooked,
the national surveillance system and local departments of
clinical microbiology provided unique identification
numbers for all patients with a positive diagnostic test.
Only hospitalized cases were included since we did not
have access to information from general practitioners for
patients with legionellosis managed in the community
setting. We defined legionellosis as hospital-acquired if a
patient had been discharged within the preceding 10 days
or if symptoms of legionellosis appeared >2 days after
hospital admission. All other cases were defined as com-
munity-acquired. A case was defined as possibly travel-
associated if the patient had been visiting a foreign coun-
try within 10 days of onset of symptoms.
Baseline data collection
The following data were collected from patient medical
records: Demographics, comorbidities, clinical signs and
symptoms at baseline, date of onset of symptoms, blood
biochemistry tests, chest X-rays, date of relevant diagnos-
tic tests, results of diagnostic tests [13], time to diagnosis,
admission to intensive care unit (ICU), complications
(disseminated intravascular coagulation, rhabdomyolysis,
myocardial infarction, cerebrovascular insult), antibiotic
treatment, and length of hospital stay.
Comorbidity at the time of admission was assessed for
each patient using the Charlson Comorbidity Index [CCI]
which is defined using 19 major disease categories. The
CCI is adapted and validated for use with hospital dis-
charge ICD-9-CM codes and predicts short- and long-
term mortality [14,15]. We used information from medi-
cal records to calculate a CURB65-score and pneumonia
severity index (PSI) risk class as markers of illness sever-
ity [16,17] (missing values scored as 0). Baseline was
defined as date of admission for community-acquired and
date of onset of symptoms for hospital-acquired cases.
Anti-legionella treatment was defined as any treatment
with macrolides, fluoroquinolones, rifampicin and/or tet-
racyclines.Jespersen et al. BMC Infectious Diseases 2010, 10:124
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Assesment of outcomes
The primary endpoint was death at 30 days from base-
line. Vital status and date of death were obtained from the
Danish Civil Registration System.
Statistical analysis
We compared the demographics, clinical and laboratory
features of CAL and HAL using χ2 or Fisher's exact test as
appropriate for categorical variables. Continuous vari-
ables were compared using two-sample t-test (normal
distribution) or Mann-Whitney U-test (non-normal dis-
tribution).
To compare mortality between patients with CAL and
HAL, we constructed Kaplan Meier plots of 30-day and
90-day mortality.
We examined predictors of 30-day mortality by logistic
regression analyses for CAL and HAL separately. For
CAL, variables identified as strong predictors of mortal-
ity (p-value < 0.1) were entered in a multivariate logistic
regression model. For variables which were interdepen-
dent (i.e. CCI score and malignancy) only the strongest
predictor was included. Variables deemed to be interme-
diary steps in the process leading to a fatal outcome (e.g.
admission to ICU or intubation) were not included in the
model. A second model was developed excluding labora-
tory tests since they as well could be seen as intermediary
steps in the process leading to a fatal outcome. In this
model we also excluded symptoms. Due to a low number
of hospital-acquired cases multivariate analysis was only
done for community-acquired cases.
Statistical analyses were performed using Stata 9.2
(Statacorp, Texas).
Science ethics
This study was approved by the Danish Data Protection
Agency (jr.-nr. 2006-41-6394) and the National Board of
Health. According to Danish law no further approval was
required at the time of collection of data.
Results
We identified 370 cases of legionellosis, 22 cases who
were never admitted to hospital and 16 cases with miss-
ing medical records were excluded. Of the 332 cases eligi-
ble for analysis 272 (81.9%) were community-acquired
and 60 (18.1%) were hospital-acquired. For CAL 241
(88.6%) were reported to the Danish surveillance system
whereas 57 cases of HAL (95%) were reported (p = 0.14).
More cases of CAL (87.5%) were classified as definitive
compared to HAL (80.0%) (p = 0.05).
Comparison of baseline characteristics
The median age was 57 years (Interquartile range [IQR]:
50-70) among CAL and 67 years (IQR: 57-74) among
HAL (p = 0.003) (table 1). Comorbidities were more com-
mon among HAL (91.7%) than among CAL (41.5%) (p <
0.001). Self-reported fever, headache, diarrhoea and tem-
perature >39.5°C were more common among CAL than
among HAL. CAL had higher median C-reactive protein
level (285 mg/L), lower plasma sodium level (132 mmol/
L), lower plasma potassium level (3.8 mmol/L) and higher
hemoglobin (8.2 mmol/L) compared to HAL (161 mg/L
(p < 0.001); 136 mmol/L (p < 0.001); 4.1 mmol/L (p <
0.001) and 7.3 mmol/L (p < 0.001) ) (Additional file 1).
Chest X-ray was abnormal in 91.9% of community-
acquired cases but only in 80.0% of hospital-acquired
cases (p < 0.001). Duration of in-hospital symptoms to
requesting a test for legionellosis (7.5 days versus 3 days,
p < 0.001) and duration of in-hospital symptoms to diag-
nosis of legionellosis (12 days versus 5.5 days) (p < 0.001)
were longer for HAL than for CAL.
For CAL and HAL, 48 and 6 patients (17.6% and 10.0%)
received treatment with an anti-legionella antibiotic
within 24 hours of baseline, respectively; 18 and 7
patients (6.6% and 11.7%, p = 0.24) received no anti-legio-
nella antibiotic during admission (table 2). Among those
receiving anti-legionella treatment, median delay from
baseline was 2 days (IQR 1-4) days for CAL and 7 days
(IQR 3-12) for HAL. For both CAL and HAL macrolide
monotherapy was the most frequent anti-legionella treat-
ment (32.7% and 30.0% of cases, respectively).
Comparison of mortality
Thirty and 90-day case fatality were 12.9% and 15.8% for
CAL, and 33.3% and 55.0% for HAL cases, respectively
(figure 1 Survival by community- or hospital-acquired
infection. Blue curve shows community-acquired cases,
red curve hospital-acquired cases). One hundred-and-
sixteen patients (42.6%) with CAL were admitted to
intensive care unit [ICU] and 37 (61.7%) with HAL (p =
0.008) (table 3). Median length of stay was 12 and 10 days
for CAL and HAL, respectively (p = 0.79).
Predictors of mortality for cal and hal
Among community-acquired cases no anti-legionella
treatment was associated with a notable increased risk of
death (Odds ratio [OR] = 11.5 (95% Confidence interval
[CI]: 2.1-64.3) (table 4). Although not statistically signifi-
cant, delay of anti-legionella treatment for more than 24
hours was associated with an increased risk of death (OR
= 3.6, 95% CI: 0.8-15.6). Other variables associated with
an increased risk of death in the unadjusted regression
analysis can be seen in table 4. In a multivariate model
including all variables with a p-value < 0.1 lymphocytosis
(OR = 33.9, 95% CI: 2.1-553.5) and hyperbilirubinemia
(OR = 7.3, 95% CI: 1.6-33.6) were independently associ-
ated with an increased risk of death; whereas hyponatri-
emia was associated with a decreased risk of death (OR =
0.2, 95% CI: 0.04-0.8) (p = 0.03). Median duration of timeJespersen et al. BMC Infectious Diseases 2010, 10:124
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Table 1: Baseline characteristics of patients with community-acquired (CAL) and hospital-acquired legionellosis (HAL).a
CAL HALb
Characteristic No. (%) (n = 272)c No. (%) (n = 60)c p-valued
Demographics
Male sex 181 (66.5) 33 (55.0) 0.09
Age, median years (IQR) 57 (50-70) 67 (57-74) 0.003*
Age group 0.002*
≤ 65 years 185 (68.0) 28 (46.7)
> 65 years 87 (32.0) 32 (53.3)
Exposure
Associated with travelling to 
another countrye
92 (33.8) 0 (0) <0.001*
Exposure to air-conditioning 33 (12.1) 0 (0) 0.004*
Part of a possible outbreak of 
legionnaires' disease
2 (0.7) 1(1.7) 0.49
Comorbid illnesses
Charlson Comorbidity Index <0.001*
= 0 170 (62.5) 13 (21.7)
= 1 61 (22.4) 12 (20.0)
≥ 2 41 (15.1) 35 (58.3)
Current smoker 147 (54.0) 17 (28.3) 0.002*
Current alcohol abuse 30 (11.0) 7 (11.7) 0.65
Selected symptoms and 
signs
Temperature >39.5°C 143 (52.6) 7 (11.7) <0.001*
Depressed consciousness 64 (23.5) 5 (8.3) 0.17
X-ray findings
Abnormal chest X-ray 250 (91.9) 48 (80.0) 0.001*
Unilateral infiltrate 188 (69.1) 37 (61.7) 0.20
Bilateral infiltrates 54 (19.9) 9 (15.0) 0.36
Severity of illness
Pneumonia severity index 
(PSI) risk class
0.74
I 19 (7.0) 3 (5.0)
II 65 (23.9) 18 (30.0)
III 76 (27.9) 15 (25.0)
IV 95 (34.9) 19 (31.7)
V 15 (5.5) 5 (8.3)
CURB-65 score 0.62
O 119 (43.8) 21 (35.0)
I 98 (36.0) 23 (38.3)
II 39 (14.3) 12 (20.0)
III 10 (3.7) 3 (5.0)
IV 2 (0.7) 1 (1.7)Jespersen et al. BMC Infectious Diseases 2010, 10:124
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from in-hospital symptoms to diagnosis was shorter
among patients with hyponatriemia compared with
patients without, 5 days and 10 days, respectively (p <
0.001). Furthermore, 18% of patients with hyponatriemia
received treatment with an anti-legionella antibiotic
within 24 hours of admission compared to 10% of
patients without hyponatriemia (p = 0.04). When replac-
ing variables comprising PSI-score from the model (age,
CCI score, confusion, hyponatriemia and blood urea
nitrogen) with PSI score ≥3 this was independently asso-
ciated with an increased risk of death (OR = 5.9, 95% CI:
1.2-28.9), whereas CURB65-score ≥ 3 was not an inde-
pendent predictor of death OR = 1.9 (95% CI: 0.4-8.9) (p
= 0.40). In a model that did not include symptoms and
laboratory tests age >65 years (OR = 2.6, 95% CI: 1.1-5.9)
and Charlson Comorbidity Index ≥2 (OR = 2.7, 95% CI:
1.1-6.5) were independent predictors of death (table 5).
Among hospital-acquired cases no variables were inde-
pendently associated with a statistically significant
i n c r e a s e d  r i s k  o f  d e a t h  t h o u g h  h i g h  o d d s  r a t i o s  w e r e
found for the following variables: No treatment with anti-
legionella antibiotics during admission, oxygen saturation
<92%, ALAT >50 U/L, lymphocytosis, any comorbidity,
PSI risk class >2, leucopenia, and anemia (table 4 and
additional file 2).
Discussion
In this historical population-based cohort study we found
that HAL had a less distinctive clinical presentation and
was associated with fewer abnormal biochemistry find-
ings than CAL. Time from in-hospital symptoms to diag-
nosis was longer for HAL than for CAL, indicating a need
for increased awareness of HAL. Legionellosis was asso-
ciated with high mortality, particularly among hospital-
acquired cases. Independent risk factors of death among
community-acquired cases were age, comorbid condi-
tions, lymphocytosis, and hyperbilirubinemia. Omission
or delay of anti-legionella treatment was a risk factor for
death among patients with CAL.
The strengths of our study include the population-
based design, a laboratory-confirmed diagnosis in all
cases, and a systematic review of patients' medical
records. In Denmark there is equal access to a public
health care system and reliable information on patients'
date of death is available from the Central Person Regis-
try.
Our study also had several limitations. Information
about the time of initiation of antibiotic treatment was
often imprecise, in most cases only the date of initiation
was recorded and some patients who actually did not
receive anti-legionella treatment within 24 hours of
admission may have been misclassified. This potential
bias would cause us to underestimate the effect of early
initiation of anti-legionella treatment. Values needed for
CURB65 and PSI scores were not available in all medical
records, therefore we may have underestimated the prog-
nostic accuracy of these two severity adjustment tools.
Furthermore, the limited number of hospital-acquired
cases reduced the power to detect variables significantly
associated with increased mortality.
Only few studies have focused on differences between
community-acquired and hospital-acquired cases of
legionellosis [18,19]. Pedro-Botet et al. [19] compared
125 hospital-acquired cases and 33 community-acquired
cases of legionellosis and found that younger age, smok-
ing, cough, thoracic pain, and extrapulmonary manifesta-
tions were more prevalent in the community-acquired
cases, while chronic lung disease, cancer, elevated blood
creatinine values, and treatment with oxygen and corti-
costeroids were more prevalent among hospital-acquired
Diagnosis
Duration of in-hospital 
symptoms to relevant 
diagnostic test for 
legionellosis, median (IQR)
3 (1-5) 7.5 (4-15.5) <0.001*
Duration of in-hospital 
symptoms to diagnosis of 
legionellosis, median (IQR)
5.5 (4-9) 12 (7-17) <0.001*
a See additional file 1 for more baseline characteristics
b Defined as hospital-acquired if the patient had been admitted within the preceding 10 days or if the patient developed symptoms
of legionellosis more than 2 days after hospital admission.
c Totals may not add up to 100% due to missing values
d Differences between the groups were analyzed with χ2 or Fisher's exact test as appropriate for categorical variables.
Continuous variables were compared using two-sample t-test (normal distribution) or Mann-Whitney U-test (non-normal distribution).
e Defined as possible travel-associated if the patient had travelled to a foreign country within 10 days of onset of symptoms.
IQR: Interquartile range.
* P-level < 0.05 is considered statistically significant.
Table 1: Baseline characteristics of patients with community-acquired (CAL) and hospital-acquired legionellosis (HAL).a (Continued)Jespersen et al. BMC Infectious Diseases 2010, 10:124
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Table 2: Comparison of antibiotic therapy for CAL and HAL.
CAL HALa
Variables No. (%) of episodes No. (%) of episodes p-valueb
Initial antibiotic therapy
Use of an anti-legionella antibioticc 34 (12.5) 5 (8.3) 0.38
Use of >1 antibiotic (± anti-legionella 
antibiotics)
54 (19.9) 20 (33.3) 0.14
Penicillin monotherapy 144 (52.9) 16 (26.7) <0.001*
Anti-legionella antibiotic treatment
Anti-legionella antibiotic ≤ 24 hoursd 48 (17.6) 6 (10.0) x
Anti-legionella antibiotic > 24 hoursd 201 (73.9) 42 (70.0) x
No anti-legionella antibiotic during 
admission
18 (6.6) 7 (11.7) 0.24
Delay of anti-legionella therapy 
(median and IQR)
Days from admission 2 (1-4) X x
Days from symptom onset 7 (5-11) 7 (3-12) 0.29
Duration of anti-legionella therapy 
(median and IQR)
Died in hospital 7 (2-13) 6 (2-13) 0.79
Discharged alive 21 (14-23) 20 (13-27) 0.65
Antibiotics used during admission
Macrolide monotherapye 87 (32.0) 18 (30.0) 0.97
Fluoroquinolone monotherapyf 4 (1.5) 3 (5.0) 0.07
Macrolide + Rifampicin 39 (14.3) 5 (8.3) 0.26
Fluoroquinolone + Rifampicin 11 (4.0) 3 (5.0) 0.67
Macrolide + Fluoroquinolone 44 (16.2) 9 (15.0) 0.95
Macrolide + Fluoroquinolone + 
Rifampicin
67 (24.6) 15 (25.0) 0.77
No anti-legionella therapy 18 (6.6) 7 (11.7) 0.18
Oral anti-legionella therapy only
Yesg 22 (8.1) 3 (5.0) 0.40
No 247 (90.8) 57 (95.0) 0.40
a A case was defined as hospital-acquired if the patient had been admitted within the preceding 10 days or if the patient developed
symptoms of legionellosis more than 2 days after hospital admission.
b Differences between the groups were analyzed with χ2 or Fisher's exact test as appropriate for categorical variables.
Continuous variables were compared using two-sample t-test (normal distribution) or Mann-Whitney U-test (non-normal distribution).
c Anti-legionella antibiotics include macrolides, quinolones, rifampicin and tetracyclines.
d For community-acquired cases time from admission. For hospital-acquired cases time from beginning of symptoms.
No comparison between groups for these variables since baseline was defined in different ways.
e The macrolides were either erythromycin, clarithromycin, roxithromycin or azithromycin
with the most commonly used being intravenous erythromycin
f Primarily intravenous ciprofloxacin
g Most commonly used anti-legionella drug adminstered orally was roxithromycin
* P-level < 0.05 is considered statistically significant.
IQR: Interquartile rangeJespersen et al. BMC Infectious Diseases 2010, 10:124
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cases in an unadjusted analysis. However, in the adjusted
analysis only smoking and blood creatinine levels
remained statistically significant. No differences were
found in clinical outcome [19]. In our study, there were
some notable differences between community-acquired
and hospital-acquired cases. Hospital-acquired cases had
less typical signs and symptoms of pneumonia compared
to community-acquired cases. This might partly be
explained by a more thorough medical history and exam-
ination when patients were admitted to the hospital com-
pared to patients already being hospitalized - leading to
information bias. Clinicians should be very observant of
the diagnosis of legionellosis since 20% of hospital-
acquired cases did not have abnormalities on chest x-rays
at onset of symptoms. There was a marked delay of
requesting testing for Legionella in HAL compared with
CAL which again stresses the need for increased aware-
ness and immediate access to diagnostics including PCR
and urinary antigen testing. With this combination of
tests a high diagnostic sensitivity is likely to be achieved
[13].
Table 3: Comparison of outcomes for CAL and HAL.
CAL HALa
Variables No. (%) No. (%) p-valueb
Admission to intensive care 
unit
116 (42.6) 37 (61.7) 0.008*
Days in intensive care, median 
days (IQR)
12 (5-20) 10 (6-23) 0.79
Mechanical ventilation 93 (34.2) 32 (53.3) 0.06
Hemodialysis 43 (15.8) 18 (30.0) 0.01*
Inotropic support 86 (31.6) 29 (48.3) 0.02*
Medical complications
Disseminated intravascular 
coagulation
9 (3.3) 3 (5.0) 0.53
Rhabdomyolysis 4 (1.5) 1 (1.7) 0.92
Myocardial infarction 5 (1.8) 4 (6.7) 0.04*
Cerebrovascular insult 5 (1.8) 0 (0) 0.29
Outcome
30-day mortalityc 35 (12.9) 20 (33.3) x
90-day mortalityc 43 (15.8) 33 (55.0) x
a A case was defined as hospital-acquired if the patient had been admitted within the preceding 10 days or if the patient developed
symptoms of legionellosis more than 2 days after hospital admission.
b Differences between the groups were analyzed with χ2 or Fisher's exact test as appropriate for categorical variables.
Continuous variables were compared using two-sample t-test (normal distribution) or Mann-Whitney U-test (non-normal distribution).
c For community-acquired cases time from admission. For hospital-acquired cases time from beginning of symptoms.
No comparison between groups for these variables since baseline was defined in different ways.
* P-level < 0.05 is considered statistically significant.
IQR: Interquartile range.
Figure 1 Survival by community- or hospital-acquired infection. 
Blue curve shows community-acquired cases, red curve hospital-ac-
quired cases.
Jespersen et al. BMC Infectious Diseases 2010, 10:124
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Table 4: Univariate predictors of 30 day mortality in patients with CAL and HAL.a
CAL HALb
Predictor variables by 
category
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Variables known at the 
time of patient 
presentation
Demographics
Age > 65 years 3.9 (1.9-8.1) <0.001* 0.7 (0.2-2.0) 0.46
Case associated with 
travelling to another 
country
0.4 (0.1-0.9) 0.03* x x
Comorbid illnesses
Any comorbidityc 2.4 (1.1-4.9) 0.02* 2.2 (0.2-21.5) 0.49
Immunosuppression 6.3 (2.7-14.8) <0.001* 1.5 (0.5-4.6) 0.48
Malignancy 4.7 (1.6-13.9) 0.005* 2.1 (0.7-6.9) 0.20
Renal insufficiency 7.2 (1.4-37.1) 0.02 0.4 (0.04-3.4) 0.38
Charlson Comorbidity 
Index ≥ 2
3.7 (1.7-8.3) 0.001* 1.5 (0.5-4.6) 0.48
Current smoker 0.5 (0.2-1.1) 0.09 0.4 (0.1-1.6) 0.21
Symptoms
Self-reported fever 0.4 (0.2-0.9) 0.03* 2.1 (0.7-6.6) 0.21
Dyspnoea 2.4 (1.1-5.1) 0.03* 0.6 (0.2-1.9) 0.42
Headache 0.1 (0.01-0.5) 0.01* 0.4 (0.05-4.3) 0.49
Confusion 1.9 (0.9-4.2) 0.01* 0.3 (0.03-2.5) 0.26
Signs
Normal pulmonary 
stethoscopy
0.2 (0.1-1.02) 0.05 1.6 (0.3-8.4) 0.56
Laboratory tests
Lymphocytosis, 
lymphocyte count >3.5 
cells 109/L
6.7 (0.9-49.6) 0.06 2.6 (0.1-45.4) 0.52
Bilirubin >23 
mikromol/L
8.3 (2.9-24.1) <0.001* 1.0 (0.3-4.1) 0.96
Creatinine >115 
mikromol/L
2.5 (1.2-5.2) 0.01* 0.7 (0.2-2.6) 0.57
Blood urea nitrogen 
>7.5 mmol/L
4.2 (1.3-13.3) 0.02* 0.9 (1.1-5.6) 0.89
Hyponatremia, sodium 
<128 mmol/L
0.3 (0.1-1.0) 0.049* 0.6 (0.1-2.6) 0.49
Hypercapnia, PaCO2 
>6 kPa
4.4 (0.97-19.9) 0.06 1.6 (0.3-10.1) 0.60
Atrial fibrillation at 
admission
2.6 (1.01-6.9) 0.048* 1.2 (0.3-5.1) 0.77
X-ray findings
Unilateral infiltrate on 
chest x-ray
0.8 (0.4-1.6) 0.46 0.4 (0.1-1.2) 0.09Jespersen et al. BMC Infectious Diseases 2010, 10:124
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Legionella-related mortality has decreased dramatically
in the United States over the last decades. Benin et al. [20]
examined 6757 confirmed cases of legionellosis from
1980-1998. During this period, case-fatality decreased
from 46% to 14% for hospital-acquired cases, and from
26% to 10% for community-acquired cases. This improve-
ment in outcome may be attributed to more prevalent use
of diagnostic tests and increased use of broad-spectrum
empirical antibiotic therapy for pneumonia [20]. The 30-
and 90-days mortality-rate in our study was higher for
both hospital-acquired and community-acquired cases
than found by Benin et al. as well as in Pedro-Botet et al.'s
study [19]. This could be explained to some extent by a
more restrictive antibiotic policy in Denmark where the
empirical antibiotic treatment for community-acquired
pneumonia is penicillin with an exception made in some
local guidelines for patients with a CURB65 score >2;
addition of anti-legionella therapy is recommended for
these patients. However, ascertainment bias must also be
taken into account, i.e. that only the more severe cases of
legionellosis tend to be diagnosed. A direct comparison
with the studies of Benin et al. and Pedro-Botet et al. is
not possible due to differences in case definitions. The
studies by Benin et al. and Pedro-Botet et al. only
included patients with Legionella pneumonia whereas we
included all patients with legionellosis. Since patients
with Pontiac fever have a lower risk of dying, mortality in
our study would probably have been even higher if we
had excluded these patients from our analyses.
Among community-acquired cases in our study, treat-
ment with an anti-legionella drug within 24 hours of
admission was associated with a decreased risk of death,
however, this did not reach statistical significance. The
lack of precision was primarily due to the limited sample
size. Delay of anti-legionella therapy has found to be asso-
ciated with an increased risk of death in other studies. A
study of Heath et al. [9] of 39 serologically confirmed
cases of legionellosis showed that the median delay in
erythromycin therapy was 6 days for survivors and 11
days in those who died. Gacouin et al. [10] showed in a
study of 43 cases with severe legionellosis that fluoroqui-
nolone administration within 8 hours of ICU admission
was associated with a reduced mortality (OR = 0.16; 95%
CI: 0.03-0.96). In our study delayed treatment with anti-
legionella antibiotics did not have a statistically signifi-
cant impact on the risk of death among hospital-acquired
cases. One contributing factor could be confounding by
indication, i.e. that the most severely ill patients tended to
receive treatment earlier.
A limited number of studies have focused on prognos-
tic factors in legionellosis. Marston et al. [21] found that
the likelihood of death from Legionella pneumonia was
Severity of illness
PSI risk class >2 9.1 (2.1-38.7) <0.01* 2.2 (0.7-2.7) 0.20
CURB65 risk class >2 3.6 (1.0-12.8) 0.045* 0.6 (0.1-6.3) 0.68
Variables known later 
during admission
Treatment for 
legionellosis
Treatment with anti-
legionella antibiotics
<24 hours from 
baselined
1 (ref.) 1 (ref.)
>24 hours from 
baselined
3.6 (0.8-15.6) 0.09 0.4 (0.1-2.0) 0.24
No treatment with 
anti-legionella 
antibiotics during 
admission
11.5 (2.1-64.3) <0.01* 6.0 (0.4-85.2) 0.19
a For community-acquired cases 30 days from admission. For hospital-acquired cases 30 days from onset of symptoms
b A case was defined as hospital-acquired if the patient had been admitted within the preceding 10 days or if the patient developed
symptoms of legionellosis more than 2 days after hospital admission.
c Immunosuppression, malignancy, chronic obstructive pulmonary disease, ischaemic heart disease, congestive heart failure, diabetes 
mellitus
or renal insufficiency.
d For community-acquired cases time from admission. For hospital-acquired cases time from beginning of symptoms.
* P-level < 0.05 is considered statistically significant
Table 4: Univariate predictors of 30 day mortality in patients with CAL and HAL.a (Continued)Jespersen et al. BMC Infectious Diseases 2010, 10:124
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Table 5: Independent predictors of 30 day mortality in patients with CAL.a
CAL
Predictor variables by category Odds ratio (95% conf. interval) P-value
Demographics
Age > 65 years 1.3 (0.5-3.7) 0.60
Case associated with travelling to another 
country
0.4 (0.1-1.4) 0.16
Comorbid illnesses
Charlson Comorbidity Index ≥ 2 2.8 (0.9-8.5) 0.08
Current smoker 0.7 (0.2-2.0) 0.46
Symptoms
Self-reported fever 0.7 (0.2-2.3) 0.51
Dyspnoea 1.6 (0.6-4.3) 0.40
Headache 0.1 (0.01-1.03) 0.05
Confusion 3.0 (0.98-9.2) 0.06
Signs
Normal pulmonary stethoscopy 0.3 (0.05-1.6) 0.16
Laboratory tests
Lymphocytosis, lymphocyte count >3.5 
cells 109/L
33.9 (2.1-553.5) 0.01*
Bilirubin >23 mikromol/L 7.3 (1.6-33.4) 0.01*
Blood urea nitrogen >7.5 mmol/L 1.9 (0.4-8.5) 0.38
Hyponatriemia, sodium <128 mmol/L 0.2 (0.04-0.8) 0.03*
Hypercapnia, PaCO2 >6 kPa 2.4 (0.3-20.4) 0.42
Fibrillatrio atriorum at admission 2.4 (0.6-9.6) 0.22
Treatment
Treatment with anti-legionella antibiotics 
< 24 hours from baselineb
0.3 (0.1-1.6) 0.16
Model without symptoms and 
laboratory tests
CAL
Predictor variables by category Odds ratio (95% conf. interval) P-value
Demographics
Age > 65 years 2.6 (1.1-5.9) 0.02*
Case associated with travelling to another 
country
0.5 (0.2-1.3) 0.15
Comorbid illnesses
Charlson Comorbidity Index ≥ 2 2.7 (1.1-6.5) 0.03*
Current smoker 0.8 (0.3-1.9) 0.56
Signs
Normal pulmonary stethoscopy 0.3 (0.1-1.2) 0.09Jespersen et al. BMC Infectious Diseases 2010, 10:124
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increased in patients who were elderly or male; this was
also true for patients with hospital-acquired infection,
renal disease, malignancy, immunosuppression, and for
those with Legionella pneumophila serogroup 6. Except
from the sex-difference in mortality these findings were
in accordance with ours. Other studies of prognostic fac-
t o r s  h a v e  o n l y  b e e n  d o n e  a m o n g  p a t i e n t s  w i t h  s e v e r e
legionellosis requiring admission to ICU. Gacouin et al.
[10] found that a SAPS II score >46, more than 5 days
duration of symptoms prior to ICU admission, and intu-
bation were associated with increased mortality in
patients with legionellosis in the ICU but some of these
factors are likely to be an integral part of the pathways
which leads from the infection to the outcome and thus
do not qualify as confounders in the statistical modeling.
El-Ebiary et al. [11] also studied prognostic factors in
patients with legionellosis requiring ICU admission and
found that APACHE II score >15 at admission and serum
sodium level <136 mmol/L were associated with a poor
prognosis. Instead of AP ACHE II or SAPS II scores we
used the PSI score and CURB65 scores and these severity
assessment tools could predict patients with an increased
risk of death among community-acquired cases in the
univariate analysis even though some observations
needed for calculation of a full score were not available.
PSI risk class >2 remained an independent risk factor in
the multivariate analysis. Surprisingly, we found hypona-
triemia to be an independent predictor of a decreased
risk of death. The association between hyponatriemia
and legionellosis is well documented. Thus, increased
awareness of legionellosis in patients with pneumonia
and hyponatremia may have caused physicians to request
diagnostic testing for legionellosis and to prescribe anti-
legionella antibiotics as observed in our study which
could explain the lower mortality in this group. We chose
a statistical model without laboratory tests since abnor-
mal values could be seen as intermediary steps in the pro-
cess leading to a fatal outcome. Likewise, we also
excluded symptoms from the model and found in consis-
tence with the study done by Marston [21] that age and
comorbidities were related to an increased risk of death.
Conclusions
Signs and symptoms of hospital-acquired legionellosis
were less pronounced than in community-acquired cases.
However, the case fatality was almost 3 times higher. The
prognosis for Danish patients with legionellosis was
worse than reported in a recent US long-term study and
we found a notable diagnostic delay in hospital-acquired
cases. The study underlines that clinical awareness is
important for the timely diagnosis and treatment espe-
cially of HAL. National guidelines for diagnosis and treat-
ment of legionellosis could raise awareness of the disease
and may improve quality of care. Studies of prognostic
factors for legionellosis could further improve the thera-
peutic approach and potentially lead to a decrease in
mortality.
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b For community-acquired cases time from admission. For hospital-acquired cases time from beginning of symptoms.
* P-level < 0.05 is considered statistically significant
Table 5: Independent predictors of 30 day mortality in patients with CAL.a (Continued)Jespersen et al. BMC Infectious Diseases 2010, 10:124
http://www.biomedcentral.com/1471-2334/10/124
Page 12 of 12
References
1. Fields BS, Benson RF, Besser RE: Legionella and Legionnaires' disease: 25 
years of investigation.  Clin Microbiol Rev 2002, 15(3):506-26.
2. Neil K, Berkelman R: Increasing incidence of legionellosis in the United 
States, 1990-2005: changing epidemiologic trends.  Clin Infect Dis 2008, 
47(5):591-9.
3. Dedicoat M, Venkatesan P: The treatment of Legionnaires' disease.  J 
Antimicrob Chemother 1999, 43(6):747-52.
4. Vergis EN, Indorf A, File TM Jr, et al.: Azithromycin vs cefuroxime plus 
erythromycin for empirical treatment of community-acquired 
pneumonia in hospitalized patients: a prospective, randomized, 
multicenter trial.  Arch Intern Med 2000, 160(9):1294-300.
5. Dournon E, Mayaud C, Wolff M, et al.: Comparison of the activity of three 
antibiotic regimens in severe Legionnaires' disease.  J Antimicrob 
Chemother 1990, 26(Suppl B):129-39.
6. Cunha BA: Clinical features of legionnaires' disease.  Semin Respir Infect 
1998, 13(2):116-27.
7. Strampfer MJ, Cunha BA: Clinical and laboratory aspects of 
Legionnaire's disease.  Smin Respir Infect 1987, 2(4):228-34.
8. Sopena N, Sabria-Leal M, Pedro-Botet ML, et al.: Comparative study of the 
clinical presentation of Legionella pneumonia and other community-
acquired pneumonias.  Chest 1998, 113(5):1195-200.
9. Heath CH, Grove DI, Looke DF: Delay in appropriate therapy of 
Legionella pneumonia associated with increased mortality.  Eur J Clin 
Microbiol Infect Dis 1996, 15(4):286-90.
10. Gacouin A, Le Tulzo Y, Lavoue S, et al.: Severe pneumonia due to 
Legionella pneumophila: prognostic factors, impact of delayed 
appropriate antimicrobial therapy.  Intensive Care Med 2002, 
28(6):686-91.
11. el-Ebiary M, Sarmiento X, Torres A, et al.: Prognostic factors of severe 
Legionella pneumonia requiring admission to ICU.  Am J Respir Crit Care 
Med 1997, 156(5):1467-72.
12. Danmarks statistik   [http://www.statistikbanken.dk/BEF1A]
13. Jespersen S, Sogaard OS, Fine MJ, Ostergaard L: The relationship 
between diagnostic tests and case characteristics in Legionnaires' 
disease.  Scand J Infect Dis 2009, 8:1-8.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of 
classifying prognostic comorbidity in longitudinal studies: 
development and validation.  J Chronic Dis 1987, 40(5):373-83.
15. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: How to measure 
comorbidity. a critical review of available methods.  J Clin Epidemiol 
2003, 56(3):221-9.
16. Lim WS, Eerden MM van der, Laing R, et al.: Defining community acquired 
pneumonia severity on presentation to hospital: an international 
derivation and validation study.  Thorax 2003, 58(5):377-82.
17. Fine MJ, Auble TE, Yealy DM, et al.: A prediction rule to identify low-risk 
patients with community-acquired pneumonia.  N Engl J Med 1997, 
336(4):243-50.
18. Helms CM, Viner JP, Weisenburger DD, Chiu LC, Renner ED, Johnson W: 
Sporadic Legionnaires' disease: clinical observations on 87 nosocomial 
and community-acquired cases.  Am J Med Sci 1984, 288(1):2-12.
19. Pedro-Botet ML, Sabria-Leal M, Haro M, et al.: Nosocomial and 
community-acquired Legionella pneumonia: clinical comparative 
analysis.  Eur Respir J 1995, 8(11):1929-33.
20. Benin AL, Benson RF, Besser RE: Trends in legionnaires disease, 1980-
1998: declining mortality and new patterns of diagnosis.  Clin Infect Dis 
2002, 35(9):1039-46.
21. Marston BJ, Lipman HB, Breiman RF: Surveillance for Legionnaires' 
disease. Risk factors for morbidity and mortality.  Arch Intern Med 1994, 
154(21):2417-22.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/124/prepub
doi: 10.1186/1471-2334-10-124
Cite this article as: Jespersen et al., Clinical features and predictors of mor-
tality in admitted patients with community- and hospital-acquired legionel-
losis: A Danish historical cohort study BMC Infectious Diseases 2010, 10:124